Healthcare professional and patient assessment of a new prefilled insulin pen versus two widely available prefilled insulin pens for ease of use, teaching and learning

Nadeau, Daniel A.; Campos, Carlos; Niemeyer, Marcus; Bailey, Timothy S.

doi:10.1185/03007995.2011.644427

Cited by 23 publications

(10 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When asked about their overall reactions to the devices, patients expressed their preference for the shape of the CZP AI and its button-free activation system. This is consistent with studies in diabetes showing that patients prefer a button-free AI over conventional push-button devices [18][19][20], suggesting that easy-togrip devices without a push-button may improve the selfinjection experience for a wide range of patients.…”

Section: Discussionsupporting

confidence: 88%

Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis

Domańska

VanLunen

Peterson

et al. 2016

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Objectives: To compare the usability of a new certolizumab pegol (CZP) autoinjector with the adalimumab, etanercept, and golimumab devices in patients with rheumatoid arthritis. Methods: Two identical studies were performed in 2013 and 2016; patients performed a simulated selfinjection with the CZP autoinjector and the most up-to-date device versions at the time in a randomized, consecutive sequence. The primary end point was the ranking of the four autoinjectors in order of preference. Device usability and intuitiveness were assessed across a range of secondary and exploratory end points. Results: The 2013 and 2016 study populations included 76 patients each; a significant majority (2013: 67%; 2016: 59%) ranked the CZP autoinjector as their most preferred device (p < 0.001). Most patients agreed that the CZP autoinjector was easier to use, start, and manipulate, and were more willing to use it than the comparator devices (p < 0.001 for all pairwise comparisons with CZP). Likert score differences also favored the CZP autoinjector regarding how easy it was to determine injection completion. The CZP autoinjector was associated with a low rate of use error. Conclusions: In both studies, the CZP autoinjector was the preferred choice compared to the alternative devices and was associated with a high level of patient satisfaction. ARTICLE HISTORY

show abstract

Section: Discussionsupporting

confidence: 88%

Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis

Domańska

VanLunen

Peterson

et al. 2016

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

show abstract

“…[35][36][37] These results were consistent when pen injector ease of use was assessed in patients and HCPs separately. 38 Since 2010, 4 prefilled insulin pen injectors from 3 major manufacturers have been available: 21 the FlexTouch and FlexPen pen injectors (Novo Nordisk), the Humalog ® pen injector/Humalog KwikPen™ (Eli Lilly), and SoloSTAR (Sanofi). Studies show that pens are becoming increasingly more user-friendly and intuitive to use.…”

Section: Discussionmentioning

confidence: 99%

Usability of the Novel Liraglutide 3.0 mg Pen Injector Among Overweight or Obese Adult Patients With or Without Prior Injection Experience

Fujioka

Sparre

Sun

et al. 2015

J Diabetes Sci Technol

View full text Add to dashboard Cite

Obesity is a chronic disease often encompassed by a multitude of serious comorbidities, making its prevention and treatment public health priorities. Globally, by 2030, the numbers of adults who are overweight ( It has been shown that an increase in BMI is directly correlated with a reduction in life expectancy and increase in obesity-related comorbidities such as type 2 diabetes mellitus (T2DM).3-5 A 5-10% weight loss can provide clinically relevant improvements in obesity-related comorbidities and quality of life (QoL).6,7 Depending on BMI classification and the number/severity of comorbidities, behavioral therapy including dietary and physical activity changes, pharmacotherapy and (in the appropriate patient) bariatric surgery are recommended. 8,9 However, achieving and maintaining weight loss by diet and physical activity alone can be challenging.10-12 Pharmacotherapy supports weight loss and Background: Obesity is associated with multiple comorbidities and increased mortality, making it an important target for treatment. However, achieving and maintaining weight loss by diet and physical activity remains challenging, and may often require pharmacotherapy. Liraglutide 3.0 mg has recently been approved for weight management in the United States, Canada, and EU. The current analysis used a summative usability test to assess safety and effectiveness, ease of use, and training requirements for the novel liraglutide 3.0 mg pen injector.

show abstract

“…This highlights that participants had a positive perception of the shield‐triggered mechanism. Previous design modifications aimed at improving the ease of pen‐injector handling and use have had a positive impact on patient confidence and preference, especially among those with impaired manual dexterity . In addition, the shield of the DV3316 hides the needle during injection, which in a similar manner to contact‐activated figure puncture lancets, may help alleviate anxiety in some people and enhance user acceptabilty .…”

Section: Discussionmentioning

confidence: 99%

“…Previous design modifications aimed at improving the ease of pen-injector handling and use have had a positive impact on patient confidence and preference, especially among those with impaired manual dexterity. 10,17,18 In addition, the shield of the DV3316 hides the needle during injection, which in a similar manner to contact-activated figure puncture lancets, may help alleviate anxiety in some people and enhance user acceptabilty. 19 Overall, a positive perception of a new pen-injector with a shield-triggered mechanism may contribute toward enhanced treatment satisfaction and adherence in patients with diabetes.…”

Section: Discussionmentioning

confidence: 99%

Injecting without pressing a button: An exploratory study of a shield‐triggered injection mechanism

Zijlstra

Coester

Heise

et al. 2018

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

AimsTo evaluate the injection success and user perception of a shield‐triggered pen‐injector mechanism.MethodsThe trial (http://ClinicalTrials.gov NCT02627287) was an exploratory, two‐centre, one‐visit, open‐label, randomized controlled trial conducted in Germany in 150 injection‐experienced individuals with type 1 or type 2 diabetes. Participants self‐administered subcutaneous injections of a placebo solution using a prototype shield‐triggered pen‐injector, DV3316 (Novo Nordisk, Bagsvaerd, Denmark), and FlexPen (Novo Nordisk, Bagsvaerd, Denmark). Injection success was evaluated on a yes/no basis by the investigator. Participant confidence, leakage of fluid and pain were evaluated after each injection. Pain and device experience were assessed after completion of all injections with each pen‐injector. Overall preference was assessed after completion of all injections with both pen‐injectors.ResultsInjection success was high with both pen‐injectors (97.0%, DV3316 vs 99.7%, FlexPen). Participant confidence in dose delivery was similar for the two devices (88% of injections with DV3316 vs 81% with FlexPen were scored as “extremely confident”). The median injection pain score on a visual analogue scale (0‐100) was 3 with DV3316 vs 4 with FlexPen after each injection, and 4 with DV3316 vs 5 with FlexPen after all injections with each device. After all injections were completed, 55% of participants reported an overall preference for DV3316 vs 21% for FlexPen.ConclusionThis study demonstrates that injection‐experienced individuals can achieve a high injection success rate with a shield‐triggered pen‐injector, with similar patient confidence and injection pain compared with FlexPen.

show abstract

Healthcare professional and patient assessment of a new prefilled insulin pen versus two widely available prefilled insulin pens for ease of use, teaching and learning

Cited by 23 publications

References 23 publications

Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis

Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis

Usability of the Novel Liraglutide 3.0 mg Pen Injector Among Overweight or Obese Adult Patients With or Without Prior Injection Experience

Injecting without pressing a button: An exploratory study of a shield‐triggered injection mechanism

Contact Info

Product

Resources

About